Skip to content
Screener

Cullinan Therapeutics, Inc. CGEM Other operating expenses

Other operating expenses at other companies

CTO
Citius Oncology, Inc.CTOR
$29.95M+301%
Vor Biopharma logo
Vor BiopharmaVOR
$35.16M+5.6%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$16.16M+24.0%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$26.89M+17.9%
Alumis Inc. logo
Alumis Inc.ALMS
$100.15M-15.8%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$159.55M+40.2%

Other financials

Income statement

See full
Revenue-
Operating income-$57.3M+24.5%
Net income-$53.7M+23.3%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$78.6M+8.0%
Total debt$2.1M+36.3%
Total equity$408.7M-30.8%
Total assets$363.8M-30.1%

Cash flow

See full
Operating cash flow-$38.2M+33.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.14B+165%
Enterprise value$1.06B+196%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio8.4×-1.4×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336717
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Research and development$44,437$61,030$86,560$102,489
General and administrative12,81714,76824,39128,305
Total operating expenses57,25475,798110,951130,794
Loss from operations(57,254)(75,798)(110,951)(130,794)
Other income (expense):
Interest income3,6485,9247,74612,504
Other expense, net(98)(181)(160)(266)

Item 1. Financial Statements.

FAQ

What is Cullinan Therapeutics, Inc.'s other operating expenses?
Cullinan Therapeutics, Inc. (CGEM) reported other operating expenses of $57.25M in Q2 2026.
How has Cullinan Therapeutics, Inc.'s other operating expenses changed year-over-year?
Cullinan Therapeutics, Inc.'s other operating expenses decreased by 24.5% year-over-year, from $75.8M to $57.25M.
What is the long-term trend for Cullinan Therapeutics, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s other operating expenses has grown at a 29.1% compound annual growth rate (CAGR), from $86.9M to $241.65M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Cullinan Therapeutics, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude